natgillin/translations-raw huggingface dataset:
The concurrent use of haematopoietic growth factors and Jakavi has not been studied.
Sočasne uporabe hematopoetskih rastnih dejavnikov in zdravila Jakavi niso proučevali.
The concurrent use of Kineret with etanercept or any other TNF antagonist is not recommended (see section 4.4).
Zdravila Kineret ni priporočljivo uporabljati sočasno z etanerceptom ali kakšnim drugim antagonistom TNF (glejte poglavje 4.4).
The concurrent use of prolonged-release and immediate-release exenatide has not been studied and is not recommended.
Sočasne uporabe eksenatida v obliki s podaljšanim sproščanjem in eksenatida v obliki s takojšnim sproščanjem niso preučevali in se ne priporoča.
The concurrent use of prolonged-release exenatide and immediate-release exenatide has not been studied and is not recommended.
Sočasne uporabe eksenatida v obliki s podaljšanim sproščanjem in eksenatida v obliki s takojšnim sproščanjem niso preučevali in se ne priporoča.
The concurrent use of prolonged-release exenatide with insulin, D-phenylalanine derivatives (meglitinides), alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied.
Sočasne uporabe eksenatida v obliki s podaljšanim sproščanjem z insulinom, derivati D-fenilalanina (meglitinidi), zaviralci alfa-glukozidaze, zaviralci dipeptil peptidaze-4 ali drugih zaviralcev receptorjev GLP-1 niso preučevali.
The concurrent use of strong CYP3A inducers, including but not limited to carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John’s wort, should be avoided (see section 4.4).
Sočasni uporabi močnih induktorjev CYP3A, med drugim tudi karbamazepina, fenobarbitala, fenitoina, rifabutina, rifampicina in šentjanževke, se je treba izogibati (glejte poglavje 4.4).
The condition cleared up in 91% of patients given Ameluz (50 out of 55), compared with 22% (7 of 32) given placebo.
91 % bolnikov, zdravljenih z zdravilom Ameluz, v primerjavi z 22 % bolnikov, ki so prejemali placebo.
The conditions of the Pregnancy Prevention Programme for lenalidomide must be fulfilled for all patients unless there is reliable evidence that the patient does not have childbearing potential.
Pri vseh bolnicah morajo biti izpolnjeni pogoji programa za preprečevanje nosečnosti v zvezi z lenalidomidom, razen če obstajajo zanesljivi dokazi, da bolnica ne more zanositi.
The conditions of the Thalidomide Celgene Pregnancy Prevention Programme must be fulfilled for all male and female patients.
Pogoji programa Thalidomide Celgene za preprečevanje nosečnosti morajo biti izpolnjeni pri vseh bolnikih in bolnicah.
The conduct and results of these tests should be recorded on your child's Patient Alert Card.
Izvedbo in rezultate teh preiskav je treba zabeležiti na opozorilni kartici.
The conduct and results of these tests should be recorded on your Patient Alert Card.
Izvedbo in rezultate teh preiskav je treba zabeležiti na opozorilni kartici za bolnika.
The conduct of these tests should be recorded on your Patient Alert Card.
Izvedba teh testov mora biti zabeležena na vaši Opozorilni kartici za bolnika.
The conduction abnormalities observed both in clinical trials and post- marketing were typically transient, asymptomatic and resolved within the first 24 hours after treatment initiation.
Prevodne motnje, ki so jih opažali tako v kliničnem preskušanju kot v obdobju po prihodu zdravila na trg, so bile praviloma prehodne in brez simptomov, izzvenele pa so v prvih 24 urah po začetku zdravljenja.
The confirmed OIRR and other efficacy results per investigator assessment are presented in Table 10.
Potrjeni OIRR in druge rezultate učinkovitosti po raziskovalčevi oceni prikazuje preglednica 10.
The connected perfusion tubing equipment of the precision pump is prefilled with the diluted Removab solution for infusion.
Povezana oprema s perfuzijsko cevko natančne črpalke je napolnjena z razredčeno raztopino zdravila Removab za infundiranje.
The consequence of treatment with thiotepa at the recommended dose and schedule is profound myelosuppression, occurring in all patients.
Posledica zdravljenja s tiotepo v priporočenem odmerku in s priporočenim režimom odmerjanja je močna mielosupresija pri vseh bolnikih.
The consequent increase in dopaminergic stimulation can lead to the dopaminergic side effects observed after treatment with COMT inhibitors.
Posledično povečanje dopaminergične stimulacije lahko vodi do dopaminergičnih neželenih učinkov opaženih po zdravljenju s COMT zaviralci.
The container and the solution should be inspected prior to use as described in section 6.6.
Vsebnik in raztopino je treba pred uporabo pregledati, kot je opisano v poglavju 6.6.
The container and the solution should be inspected prior to use.
Vsebnik in raztopino je treba pred uporabo pregledati.
The container of this medicinal product contains latex rubber.
Vsebnik zdravila vsebuje gumo iz lateksa.
The container of this vaccine contains latex rubber.
Vsebnik tega cepiva vsebuje gumo iz lateksa.
The container should be gently inverted to ensure adequate mixing.
Vsebnik morate nežno obrniti, da zagotovite zadostno mešanje.
The container should be gently inverted to ensure adequate mixing.
Vsebnik nežno obračajte, da se vsebina ustrezno premeša.
The content and format of the MULTAQ Information Card and the Prescriber check list, together with the communication and distribution plan should be agreed with the National Competent Authority in each Member State prior to distribution.
O vsebini in obliki informativne kartice o zdravilu MULTAQ in o kontrolnem seznamu za predpisovalca, ter o načrtu komunikacije in distribucije le-teh, se je potrebno predhodno uskladiti s pristojnimi nacionalnimi organi v vsaki državi članici.
The content of a full pipette is applied onto the animal’s skin, after parting the fur.
Vsebina celotne merilne kapalke se nanese na kožo živali po odmiku kožuha.
The content of one full applicator (appropriate to the cat’s weight) is applied directly to the cat’s skin after parting the hair, in one spot on the middle of the neck.
Najprej je treba razmakniti dlako na enem mestu na sredi mačkinega vratu, potem pa vsebino enega polnega aplikatorja (ki ustreza telesni masi mačke) nanesti neposredno na kožo.
The content of one full Bravecto pipette is applied to the dog or cat’s skin between the shoulder blades of the dog and at the base of the skull of the cat.
Vsebina polne merilne kapalke zdravila Bravecto se nanese na kožo psa ali mačke, in sicer med lopatice pri psu in spodnji del lobanje pri mački.
The content of one full Certifect pipette (appropriate to the dog’s weight) is applied directly to the dog’s skin, after parting its fur, in two separate spots (halfway down the back of the neck, and at the base of the neck).
Vsebina ene polne merilne kapalke zdravila Certifect se (glede na telesno maso psa) nanese neposredno na kožo psa, tako da se razmakne dlaka in se zdravilo nanese na dve različni mesti (na zgornji del hrbta in na zatilje).
The content of one full Vectra 3D applicator is applied directly to the dog’s skin, after parting its fur, either in one or more spots on the back, depending on the dog’s weight, or in a continuous line along the centre of the back from the base of the tail to the shoulder blades.
Vsebina enega celotnega aplikatorja zdravila Vectra 3D se nanese neposredno na kožo psa po razmiku dlake na eno ali več mest na hrbtu, odvisno od telesne mase psa, ali v neprekinjeni črti po sredini hrbta od začetka repa do lopatic.
The content of one full Vectra Felis applicator is applied directly to the cat’s skin, after parting its fur, at the base of the cat’s head.
Vsebina enega polnega aplikatorja zdravila Vectra Felis se nanese neposredno na mačkino kožo med razmaknjeno dlako na zatilju njene glave.
The content of one tube covers a treatment area of 25 cm2 (e.g.
Vsebina tube zadošča za zdravljenje površine 25 cm2 (npr.
The content of sodium is greater than 1 mmol (up to 37 mg per dose).
Vsebnost natrija je večja od 1 mmol (do 37 mg na odmerek).
The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25–27 °C. Gently swirl the ampoule(s) to disperse the contents.
5 Vsebina ampul(e) se hitro otopi, ko jo potopite v čisto vodo pri temperaturi 25–27 °C. Ampulo(e) narahlo vrtite, da se vsebina dispergira.
The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25–27 °C. Gently swirl the ampoule(s) to disperse the contents.
Vsebina ampul(e) se hitro otopi, ko jo potopite v čisto vodo pri temperaturi 25–27 °C. Ampulo(e) narahlo vrtite, da se vsebina dispergira.
The content of the prefilled syringe should be visually inspected for any foreign particulate matter and/or change in physical appearance prior to administration.
Pred aplikacijo je vsebino napolnjene injekcijske brizge potrebno vizualno pregledati glede morebitne prisotnosti tujih delcev in/ali spremenjenega fizikalnega videza.
The content of the prefilled syringe should be visually inspected for any foreign particulate matter and/or change in physical appearance prior to administration.
Pred uporabo je potrebno vsebino napolnjene injekcijske brizge vizualno pregledati glede morebitne prisotnosti tujih delcev in/ali spremenjenega fizikalnega videza.
The content of the syringe should be inspected visually both before and after shaking for any foreign particulate matter and/or abnormal physical appearance prior to administration.
Pred cepljenjem morate vsebino napolnjene injekcijske brizge, preden jo pretresete in po tem, pregledati glede morebitnih tujkov in/ali neobičajnega fizikalnega videza.
The content of the tube should be applied to one treatment area of 25 cm2.
Vsebino tube je treba nanesti na eno zdravljeno površino velikosti 25 cm2.
The contents are poured into a drinking glass, the jar filled a second and third time with water and the contents transferred into the drinking glass, so that approximately 30 ml of test solution is obtained.
Vsebino je treba zliti v kozarec in nato plastenko še drugič in tretjič napolniti z vodo ter dodati vsebini v kozarcu tako, da nastane približno 30 ml raztopine.
The contents are poured into a drinking glass, the jar filled a second and third time with water and the contents transferred into the drinking glass, so that approximately 30 ml of test solution is obtained.
Vsebino je treba zliti v kozarec in nato vsebnik še drugič in tretjič napolniti z vodo ter dodati vsebini v kozarcu tako, da nastane približno 30 ml raztopine.
The contents must be clear and colourless.
Vsebina mora biti bistra in brezbarvna.
The contents of a cup (1,000 doses only) can be added to Solvent Oculo/Nasal using the included adapter and administered after connecting the included dropper.
Vsebino merice (samo 1.000 odmerkov) lahko dodate vehiklu Oculo/Nasal s pomočjo priloženega adapterja in jo daste živalim, ko ste namestili priloženo kapalko.
The contents of a full pipette are applied directly to the skin between the shoulder blades, after parting the fur.
Vsebino polne pipete nanesemo neposredno na kožo med lopaticama, pri čemer živali razmaknemo dlako.
The contents of a single vial of Versican Plus DHPPi or Versican Plus Pi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Vsebino viale cepiva Versican Plus DHPPi ali Versican Plus Pi je treba rekonstituirati z vsebino viale cepiva Versican Plus L4 (namesto vehikla).
The contents of a single vial of Versican Plus DHPPi should be reconstituted with the contents of a single vial of Versiguard Rabies (instead of the solvent).
Vsebino viale zdravila Versican Plus DHPPi je treba rekonstituirati z vsebino viale zdravila Versiguard Rabies (namesto vehikla).
The contents of a single vial of Versican Plus Pi should be reconstituted with the contents of a single vial of Versican Plus L4 (instead of the solvent).
Vsebino viale zdravila Versican Plus Pi je treba rekonstituirati z vsebino viale zdravila Versican Plus L4 (namesto vehikla).
The contents of a single vial of Versican Plus Pi should be reconstituted with the contents of a single vial of Versiguard Rabies (instead of the solvent).
Vsebino viale zdravila Versican Plus Pi je treba rekonstituirati z vsebino viale zdravila Versiguard Rabies (namesto vehikla).
The contents of one ampoule should be emptied into the medication reservoir of the Tolero nebuliser handset and administered by inhalation until no medicine is left in the reservoir.
Vsebina ene ampule se izlije v vsebnik za zdravilo nebulatorje Tolero in inhalira, dokler v vsebniku ni več zdravila.
The contents of one Colobreathe capsule should be inhaled twice a day using the Turbospin inhaler.
Vsebina ene kapsule zdravila Colobreathe se inhalira dvakrat na dan s pomočjo inhalatorja Turbospin.
The contents of one full Activyl pipette (appropriate to the animal and its weight) is applied directly to the skin, after parting the animals fur, onto the back of the cat’s neck at the base of its head, or between the shoulder blades and along the back of dogs.
Vsebina ene cele kapalke zdravila Activyl (primerne glede na žival in njeno težo) se nanese neposredno na kožo, potem ko ste razmaknili dlako živali, in sicer na zatilje pri mačkah ali med lopatice in vzdolž hrbta pri psih.
The contents of one syringe will treat horses weighing up to 600 kg.
Vsebina ene brizge zadošča za zdravljenje konja s telesno maso do 600 kg.
The contents of Sivextro should be reconstituted with 4 mL of water for injections, and be swirled gently until the powder has dissolved entirely.
Vsebino viale Sivextro je treba rekonstituirati s 4 ml vode za injekcije in vialo nežno obračati, dokler se prašek popolnoma ne raztopi.
The contents of the NeoSpect vial are not radioactive; however, after the addition of sodium pertechnetate (99mTc) solution for injection, adequate shielding of the final preparation must be maintained.
Vsebina NeoSpect viale ni radioaktivna; vendar je po dodatku raztopine natrijevega pertehnetata (99mTc) za injiciranje potrebno zagotavljati ustrezno zaščito pred sevanjem končnega pripravka.
The contents of the pack are: one vial of RIXUBIS 250, 500, 1000, 2000 or 3000 IU powder in a glass vial with a rubber stopper
Vsebnosti pakiranja je: ena viala praška RIXUBIS 250, 500, 1000, 2000 ali 3000 i.e. v stekleni viali z zamaškom iz gume,
The contents of the sachet should be added to a glass of orange or tomato juice.
Vsebino vrečke je treba stresti v kozarec pomarančnega ali paradižnikovega soka.
The contents of the single dose prefilled syringe should be shaken well and administered aseptically by subcutaneous injection.
Vsebino enoodmerne brizge pred uporabo pretresemo in apliciramo subkutano.
The contents of the single dose syringe should be shaken well and administered aseptically by subcutaneous injection.
Vsebino enoodmerne brizge pred uporabo pretresemo in apliciramo subkutano.
the contents of the syringe must be dispensed into an intravenous bag (or syringe) which already contains the calculated amount of the selected diluent.
vsebino brizge morate prestaviti v vrečko (ali brizgo) za intravensko uporabo, v katero ste prej že dali izračunano količino izbranega redčila.
the contents of the syringe must be dispensed into an intravenous bag (or syringe) which already contains the calculated amount of the selected diluent.
vsebino brizge morate prestaviti v vrečko ali brizgo za intravensko uporabo, v katero ste že dali izračunano količino izbranega redčila.
The contents of the tube of RotaTeq are given directly into the baby’s mouth.
Vsebino tube zdravila RotaTeq je treba dati neposredno v usta dojenčka.
The contents of the two vials are mixed together before use to make up a suspension for injection.
Vsebini obeh vial se pred uporabo zmešata v suspenzijo za injiciranje.
The contents of the vial containing 250 mg telavancin must be reconstituted with 15 ml of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection to obtain a concentration of approximately 15 mg/ml (total volume of approximately 17 ml).
Vsebino viale z 250 mg telavancina morate rekonstituirati s 15 ml raztopine dekstroze 50 mg/ml (5 %) za injiciranje ali vode za injekcije ali raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje, da dobite koncentracijo približno 15 mg/ml (skupen volumen približno 17 ml).
The contents of the vial containing 250 mg telavancin must be reconstituted with 15 ml of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection to obtain a concentration of approximately 15 mg/ml (total volume of approximately 17 ml).
Vsebino viale z 250 mg telavancina morate rekonstituirati s 15 ml raztopine dekstroze 50 mg/ml (5 %) za injiciranje ali vode za injekcije ali raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje, da pridobite koncentracijo približno 15 mg/ml (skupen volumen približno 17 ml).
The contents of the vial containing 750 mg telavancin must be reconstituted with 45 ml of either dextrose 50 mg/ml (5%) solution for injection, or water for injections or sodium chloride 9 mg/ml (0.9%) solution for injection to obtain a concentration of approximately 15 mg/ml (total volume of approximately 50 ml).
Vsebino viale s 750 mg telavancina morate rekonstituirati s 45 ml raztopine dekstroze 50 mg/ml (5 %) za injiciranje ali vode za injekcije ali raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje, da dobite koncentracijo približno 15 mg/ml (skupen volumen približno 50 ml).
The contents of the vial should be used immediately after piercing of the rubber stopper.
Vsebino viale porabite takoj, ko prebodete gumijasto zaporko.
The contents of Zinforo vial should be reconstituted with 20 ml of sterile water for injections.
Vsebino viale zdravila Zinforo je treba pripraviti z 20 ml sterilne vode za injekcije.
The contents should be swirled gently during dissolution.
Vsebino med raztapljanjem previdno vrtite.
The contents should now be completely dissolved.
Vsebina naj bi bila zdaj popolnoma raztopljena.
The continued co-administration of ciclosporin and Rapamune as maintenance therapy cannot be recommended.
Neprekinjeno sočasno zdravljenje s ciklosporinom in zdravilom Rapamune kot vzdrževalno zdravljenje ni priporočljivo.
The continuous low dose of deslorelin will reduce the functionality of the male reproductive organs, libido and spermatogenesis and lower the plasma testosterone levels, from 4 to 6 weeks after implantation.
Stalen majhen odmerek deslorelina bo 4-6 tednov po implantaciji zmanjšal funkcionalnost moških reprodukcijskih organov, libido in spermatogenezo in znižal plazemsko koncentracijo testosterona.
The contraceptive effect is therefore anticipated to be unaffected when co­administered with liraglutide.
Zato ni verjetno, da bi sočasno zdravljenje z liraglutidom vplivalo na kontracepcijski učinek.
the contraceptive pill or other hormone treatments with ethinylestradiol, hormone treatments with danazol
kontracepcijske tabletke ali druga hormonska zdravljenja z etinilestradiolom, hormonska zdravljenja z danazolom
the contraceptive pill or other hormone treatments with ethinylestradiol, hormone treatments with danazol
kontracepcijske tabletke ali druga hormonska zdravljenja z etinilestradiolom, hormonska zdravljenja z danazolom,
the contraceptive pill, hormone treatments with ethinylestradiol, or hormone treatments with danazol
kontracepcijske tablete, hormonska zdravljenja z etinilestradiolom ali hormonska zdravljenja z danazolom,
The contraindication of Cimzia in patients with history of moderate to severe heart failure (NYHA III/IV), and potential risk of congestive heart failure being worsened by Cimzia,
Kontraindikacije zdravila Cimzia pri bolnikih z anamnezo zmerne do hude srčne odpovedi (NYHA III/IV) in možno tveganje za poslabšanje kongestivne odpovedi srca zaradi zdravila Cimzia
the contraindications of pregnancy and breastfeeding, genital bleeding of unknown aetiology or for reasons other than uterine fibroids, and uterine, cervical, ovarian or breast cancer.
kontraindikacije nosečnosti in dojenja, krvavitev iz spolovil z neznano etiologijo ali zaradi drugih razlogov razen materničnih leiomiomov in raka maternice, materničnega vratu, jajčnikov ali dojke,
The contribution of prior immunosuppressive therapy to the development of PML in Tecfidera treated patients is unknown.
Prispevek predhodnega zdravljenja z imunosupresivnimi zdravili na razvoj PML pri bolnikih, zdravljenih z zdravilom Tecfidera, ni znan.
The contribution of renal excretion to the total clearance was low (0.649% of dose, 26.3% gCV).
Prispevek ledvičnega izločanja k skupnemu očistku je bil majhen (0,649 % odmerka, 26,3 % gCV).
The contribution of the initial 175 mg doses to the efficacy outcome is currently not known.
Prispevek začetnih 175-miligramskih odmerkov k učinkovitosti zdravljenja je trenutno neznan.
The contribution of the medicinal product’s diuretic and natriuretic effect to its hypotensive activity has still to be defined.
Prispevek diuretičnega in natriuretičnega učinka tega zdravila k njegovemu antihipertenzivnemu delovanju bo treba še opredeliti.
The contribution of the medicinal product’s diuretic and natriuretic effect to its hypotensive activity has still to be defined.
Prispevek diuretičnega in natriuretičnega učinka zdravila k hipotenzivnemu še ni podrobneje raziskan.
The contribution of unchanged 14C – telaprevir and VRT-127394 towards total radioactivity recovered in faeces was 31.8% and 18.7%, respectively.
Prispevek nespremenjenega, s C14 označenega telaprevirja k skupni količini radioaktivnosti, izmerjene v blatu, je znašal 31,8%, za VRT-127394 pa je znašal 18,7%.
The control regimen (Pbo/PR) had a fixed treatment duration of 48 weeks, with telaprevir-matching placebo for the first 12 weeks and peginterferon alfa-2a and ribavirin for 48 weeks.
Za kontrolno shemo (Pbo/PR) je bilo določeno trajanje zdravljenja 48 tednov, enako za telaprevir kot za placebo v prvih 12. tednih, in z jemanjem peginterferona alfa-2a in ribavirina v času 48 tednov.
The control regimen in adolescents aged 12 through 17 years (n=48) and children aged 6 months to less than 12 years (n=102) consisted of placebo for aprepitant on Days 1, 2 and 3 in combination with ondansetron on Day 1.
Kontrolna shema za mladostnike, stare od 12 do 17 let (n = 48), in otroke, stare od 6 mesecev do manj kot 12 let (n = 102), je obsegala placebo 1., 2. in 3. dan v kombinaciji z ondansetronom 1. dan.
The control was non- activated autologous peripheral blood mononuclear cells.
Kontrola je bila sestavljena iz neaktiviranih avtolognih mononuklearnih celic iz periferne krvi.
The controlled distribution programme is aimed to manage the product supply chain to ensure that cold storage requirements are observed and to control the distribution of IMLYGIC to qualified centres and up to the patients.
Program nadzorovane distribucije je namenjen za upravljanje dobavne verige zdravila, da se zagotovi, da se upoštevajo zahteve za skladiščenje na hladnem, in da se nadzoruje distribucijo zdravila IMLYGIC do kvalificiranih centrov in do bolnikov.
The controlled distribution system includes the use of a patient card and/or equivalent tool for prescribing and/or dispensing controls, and the collecting of detailed data relating to the indication in order to monitor closely the off-label use within the national territory.
Nadzorovani sistem distribucije vključuje uporabo bolnikove kartice in/ali enakovrednega orodja za kontrolo predpisovanja in/ali izdajanja zdravila in zbiranje natančnih podatkov v zvezi z indikacijami, kar omogoča natančno spremljanje nenamenske uporabe na nacionalnem območju.
The controller is white with the identifier ‘IONSYS®’ and has a digital display, a light window, and a recessed dose activation button.
Upravljalnik je bel z napisom »IONSYS®« ter ima digitalni prikazovalnik, svetlobno okence in vdrt gumb za aktivacijo odmerka.
The controller will ‘beep’ once and the status light will turn green.
Krmilnik enkrat zapiska in lučka stanja se spremeni na zeleno.